Daniel Zabransky
@danielzabransky.bsky.social
Assistant professor of oncology at Johns Hopkins. Physician-scientist studying GI cancers.
Reposted by Daniel Zabransky
A study in Nature Communications reports dynamics of age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors. go.nature.com/3GlO49I #immunosky #medsky 🧪
April 24, 2025 at 4:27 PM
A study in Nature Communications reports dynamics of age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors. go.nature.com/3GlO49I #immunosky #medsky 🧪
Reposted by Daniel Zabransky
New study led by @danielzabransky.bsky.social lab
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors - Nature Communications
The aging immune system is characterized by changes in immune cell frequencies and functionality. Here the authors report dynamics of age-related divergence of circulating immune responses in patients...
nature.com
April 21, 2025 at 3:02 PM
New study led by @danielzabransky.bsky.social lab
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells